Funding Opportunity RFA-DK-26-001 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications that propose a Center for Diabetes Translation Research (CDTR) to advance research along the spectrum of diabetes T2-T4 translational research (i.e., bedside to clinical practice and community settings, dissemination and implementation). The purpose of this Centers program is to accelerate innovation of diabetes translation to maximize positive impacts of research on population health through activities and core services that offer specialized expertise, tools, education, and support. An emphasis on novel methods and research to address health equity and reduce diabetes-related health disparities is encouraged. Novel research cores designed to improve other aspects of person-centered, community, and population health are also encouraged with justification of how such findings or strategies may be adapted to meaningfully inform disparity-reduction approaches. A scientific base reflecting academic institutions and diverse organizational collaborators (e.g., healthcare systems, community organizations, health departments, human services) is expected to foster a Center framework necessary for improving population health. CDTRs are based on the core concept whereby shared resources aimed at fostering productivity, synergy, and novel research ideas among the funded investigators are supported in a cost-effective manner.

Funding Opportunity PAR-24-330 from the NIH Guide for Grants and Contracts. This PAR is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025. The objective of this funding opportunity is to support non-pharmacological interventions to promote sleep health, reduce sleep health disparities, and examine sleep as a modifiable factor to reduce health disparities for other health outcomes among populations that experience health disparities.

Notice NOT-OH-25-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-25-002 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

Notice NOT-MH-25-085 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-25-007 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This Informatics Tools for the Pangenome NOFO will provide multiple awards to develop informatics tools that enable uptake and use of the improved pangenome reference. Emphasis will be on tools for common use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics. Possible examples include selecting the best subset of linear genomes or paths along the graph for a given set of samples, visualizing complex variation, and annotating regulatory elements and disease associations.

Funding Opportunity PAR-25-298 from the NIH Guide for Grants and Contracts. The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than $6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this NOFO, a college is a stand-alone entity and not a component of a university system.

Funding Opportunity PAR-24-286 from the NIH Guide for Grants and Contracts. The primary goal of the NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22) Program (hereafter abbreviated as the NIMH Career Transition K22 Program) is to provide support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (DIRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields

Notice NOT-GM-25-014 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-016 from the NIH Guide for Grants and Contracts

Notice NOT-CA-25-017 from the NIH Guide for Grants and Contracts

Notice NOT-OH-25-004 from the NIH Guide for Grants and Contracts

Notice NOT-EY-25-002 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-100 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This NOFO provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.

Notice NOT-AR-24-022 from the NIH Guide for Grants and Contracts

Notice NOT-DC-25-016 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-26-056 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

Funding Opportunity RFA-DA-26-055 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Opportunity Announcement (NOFO) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

Funding Opportunity PAR-25-026 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Funding Opportunity PAR-25-025 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.